Cite
HARVARD Citation
Kaesmann, L. et al. (n.d.). 279 Durvalumab after chemoradiotherapy for PD-L1 expressing inoperable stage III NSCLC impacts local-regional control and overall survival. Journal for immunotherapy of cancer. p. A304. [Online].